<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614743</url>
  </required_header>
  <id_info>
    <org_study_id>ROS-INC-12</org_study_id>
    <nct_id>NCT01614743</nct_id>
  </id_info>
  <brief_title>A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea</brief_title>
  <official_title>A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, randomized placebo controlled pilot study comparing the efficacy&#xD;
      and safety of incobotulinumtoxinA versus saline injections to the cheek region in patients&#xD;
      with rosacea.&#xD;
&#xD;
      The pilot study will enroll and treat a total of 10 subjects who present with rosacea of the&#xD;
      cheek area. Upon study entry, subjects will be randomized to receive treatment with&#xD;
      incobotulinumtoxinA or bacteriostatic saline to the cheek area. Study treatment will be&#xD;
      prepared by an unblinded designee and both Physician Investigator (PI) and subject will&#xD;
      remain blinded for the duration of the study. At the 16 week visit, control subjects will&#xD;
      enter the rescue arm portion of the study and all study subjects will receive treatment with&#xD;
      incobotulinumtoxinA to the cheek areas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in the Rosacea Clinical Score Card</measure>
    <time_frame>baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
    <description>Live rosacea assessment for each side of the face using the Rosacea Clinical Scorecard for clinical assessment.The Rosacea Clinical Scorecard assesses the primary signs and symptoms of rosacea and is graded as absent (0), mild (1), moderate (2) or severe (3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
    <description>Rate of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale Score at Baseline, 1, 4, 12, 16, 17, and 20 Weeks</measure>
    <time_frame>baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
    <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale.&#xD;
Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale includes three facets of self-esteem: Appearance, Performance, and Social The scale has a range of 20-100. A score closer to 100 signifies higher self-esteem, while a score closer to 20 signifies lower seld-esteem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>week 1, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
    <description>4-point categorical assessment of patient satisfaction with treatment.&#xD;
Highly Satisfied- Optimal cosmetic result&#xD;
Very Satisfied- Obvious improvement in appearance form the initial condition, but not completely optimal for this subject&#xD;
Satisfied- Marked improvement in appearance from initial condition&#xD;
Unsatisfied- The appearance is essentially the same or worse as the original condition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>IncobotulinumtoxinA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IncobotulinumtoxinA</intervention_name>
    <description>Experimental injection given at baseline and Week 16</description>
    <arm_group_label>IncobotulinumtoxinA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacteriostatic saline</intervention_name>
    <description>Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females between 18 and 65 years of age.&#xD;
&#xD;
          2. Subjects presenting with rosacea in the cheek area.&#xD;
&#xD;
          3. Willingness and ability to comply with protocol requirements, including returning for&#xD;
             follow-up visits and abstaining from exclusionary procedures for the duration of the&#xD;
             study.&#xD;
&#xD;
          4. Subjects of childbearing potential must have a negative urine pregnancy test result at&#xD;
             Visit 1 and be willing able to use an acceptable method of birth control (e.g.,&#xD;
             barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical&#xD;
             sterilization, abstinence) during the study. Women will not be considered of&#xD;
             childbearing potential if one of the following is documented on the medical history:&#xD;
&#xD;
               -  postmenopausal for at least 12 months prior to study drug administration&#xD;
&#xD;
               -  without a uterus and/or both ovaries&#xD;
&#xD;
               -  has had a bilateral tubal ligation for at least 6 months prior to study drug&#xD;
                  administration.&#xD;
&#xD;
               -  absence of an other physical condition according to the PI's discretion&#xD;
&#xD;
          5. Willingness and ability to provide written photo consent and adherence to photography&#xD;
             procedures (i.e., removal of jewelry and makeup).&#xD;
&#xD;
          6. Willingness and ability to provide written informed consent prior to performance of&#xD;
             any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a&#xD;
             reliable form of birth control.&#xD;
&#xD;
          2. Subjects with a known allergy or sensitivity to any component of the study medications&#xD;
             or anesthesia.&#xD;
&#xD;
          3. Topical or oral rosacea treatments within the past 2 weeks.&#xD;
&#xD;
          4. Subjects with a significant systemic illness or illness localized to the areas of&#xD;
             treatment.&#xD;
&#xD;
          5. Botulinum toxin to the face within the past 6 months.&#xD;
&#xD;
          6. Significant concurrent illness such as diabetes, epilepsy, lupus, or congestive heart&#xD;
             failure.&#xD;
&#xD;
          7. Concurrent skin condition affecting area to be treated.&#xD;
&#xD;
          8. Prior surgery on the area to be treated within 3 months of initial treatment or during&#xD;
             the study.&#xD;
&#xD;
          9. History or evidence of keloids or hypertrophic scarring.&#xD;
&#xD;
         10. Subjects currently using aminoglycoside antibiotics, curare-like agents or other&#xD;
             agents that might interfere with neuromuscular function.&#xD;
&#xD;
         11. Subjects with a diagnosis of Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic&#xD;
             Lateral Sclerosis, or any other disease that might interfere with neuromuscular&#xD;
             function or current facial palsy.&#xD;
&#xD;
         12. Current history of chronic drug or alcohol abuse.&#xD;
&#xD;
         13. Concurrent therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study medication.&#xD;
&#xD;
         14. Subjects who, in the Investigator's opinion, have a history of poor cooperation,&#xD;
             nonÂ¬compliance with medical treatment or unreliability.&#xD;
&#xD;
         15. Enrollment in any active study involving the use of investigational devices or drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.denovaresearch.com</url>
    <description>DeNova Research Website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <results_first_submitted>February 6, 2019</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DeNova Research</investigator_affiliation>
    <investigator_full_name>Steven H. Dayan</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IncobotulinumtoxinA at Baseline and Week 16</title>
          <description>IncobotulinumtoxinA: Experimental injection given at baseline and Week 16</description>
        </group>
        <group group_id="P2">
          <title>Placebo at Baseline, Then incobotulinumtoxinA at 16 Weeks</title>
          <description>Bacteriostatic saline: Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5">Subject in the placebo group (5) also received the treatment (IncobotulinumtoxinA) at Visit 5.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - IncobotulinumtoxinA</title>
          <description>Experimental injection given at baseline and Week 16</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Bacteriostatic Saline</title>
          <description>Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="26" upper_limit="61"/>
                    <measurement group_id="B2" value="53" lower_limit="47" upper_limit="61"/>
                    <measurement group_id="B3" value="47" lower_limit="26" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in the Rosacea Clinical Score Card</title>
        <description>Live rosacea assessment for each side of the face using the Rosacea Clinical Scorecard for clinical assessment.The Rosacea Clinical Scorecard assesses the primary signs and symptoms of rosacea and is graded as absent (0), mild (1), moderate (2) or severe (3).</description>
        <time_frame>baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - IncobotulinumtoxinA</title>
            <description>IncobotulinumtoxinA: Experimental injection given at baseline and Week 16</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Bacteriostatic Saline</title>
            <description>Bacteriostatic saline: Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Rosacea Clinical Score Card</title>
          <description>Live rosacea assessment for each side of the face using the Rosacea Clinical Scorecard for clinical assessment.The Rosacea Clinical Scorecard assesses the primary signs and symptoms of rosacea and is graded as absent (0), mild (1), moderate (2) or severe (3).</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Diff from baseline, Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.49"/>
                    <measurement group_id="O2" value="-0.00063" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Diff from baseline, Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.60"/>
                    <measurement group_id="O2" value="-0.34" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Diff from baseline, Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.61"/>
                    <measurement group_id="O2" value="-0.13" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Diff from baseline, Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.48"/>
                    <measurement group_id="O2" value="-0.51" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Diff from baseline, Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.62"/>
                    <measurement group_id="O2" value="-0.83" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Diff from baseline, Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="8.85"/>
                    <measurement group_id="O2" value="-0.7" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events</title>
        <description>Rate of adverse events</description>
        <time_frame>baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - IncobotulinumtoxinA</title>
            <description>IncobotulinumtoxinA: Experimental injection given at baseline and Week 16</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Bacteriostatic Saline</title>
            <description>Bacteriostatic saline: Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events</title>
          <description>Rate of adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale Score at Baseline, 1, 4, 12, 16, 17, and 20 Weeks</title>
        <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale.&#xD;
Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale includes three facets of self-esteem: Appearance, Performance, and Social The scale has a range of 20-100. A score closer to 100 signifies higher self-esteem, while a score closer to 20 signifies lower seld-esteem.</description>
        <time_frame>baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - IncobotulinumtoxinA</title>
            <description>IncobotulinumtoxinA: Experimental injection given at baseline and Week 16</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Bacteriostatic Saline</title>
            <description>Bacteriostatic saline: Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale Score at Baseline, 1, 4, 12, 16, 17, and 20 Weeks</title>
          <description>Self-esteem change will be determined by patient self-evaluation using the Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale.&#xD;
Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale includes three facets of self-esteem: Appearance, Performance, and Social The scale has a range of 20-100. A score closer to 100 signifies higher self-esteem, while a score closer to 20 signifies lower seld-esteem.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="8.19"/>
                    <measurement group_id="O2" value="35.2" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" spread="11.8"/>
                    <measurement group_id="O2" value="36.0" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="15.7"/>
                    <measurement group_id="O2" value="34.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="12.6"/>
                    <measurement group_id="O2" value="32.2" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="11.0"/>
                    <measurement group_id="O2" value="34.6" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="10.4"/>
                    <measurement group_id="O2" value="33.6" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" spread="12.2"/>
                    <measurement group_id="O2" value="34.2" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>4-point categorical assessment of patient satisfaction with treatment.&#xD;
Highly Satisfied- Optimal cosmetic result&#xD;
Very Satisfied- Obvious improvement in appearance form the initial condition, but not completely optimal for this subject&#xD;
Satisfied- Marked improvement in appearance from initial condition&#xD;
Unsatisfied- The appearance is essentially the same or worse as the original condition.</description>
        <time_frame>week 1, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - IncobotulinumtoxinA</title>
            <description>IncobotulinumtoxinA: Experimental injection given at baseline and Week 16</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Bacteriostatic Saline</title>
            <description>Bacteriostatic saline: Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>4-point categorical assessment of patient satisfaction with treatment.&#xD;
Highly Satisfied- Optimal cosmetic result&#xD;
Very Satisfied- Obvious improvement in appearance form the initial condition, but not completely optimal for this subject&#xD;
Satisfied- Marked improvement in appearance from initial condition&#xD;
Unsatisfied- The appearance is essentially the same or worse as the original condition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.76"/>
                    <measurement group_id="O2" value="3.8" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.52"/>
                    <measurement group_id="O2" value="3.6" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.0"/>
                    <measurement group_id="O2" value="3.3" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.52"/>
                    <measurement group_id="O2" value="3.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.0"/>
                    <measurement group_id="O2" value="2.9" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.52"/>
                    <measurement group_id="O2" value="2.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - IncobotulinumtoxinA</title>
          <description>Experimental injection given at baseline and Week 16</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Bacteriostatic Saline</title>
          <description>Placebo at baseline, incobotulinumtoxinA at 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of this study was a very small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven H Dayan, MD</name_or_title>
      <organization>DeNova Research</organization>
      <phone>312-335-2070</phone>
      <email>sdayan@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

